Abstract
Based on the N-terminal hexapeptide product of hydrolysis (EDVVCC) at HCV NS5A/5B junction, three modified groups of compounds are built. The first group contains linear peptides while the second and third groups contain P1-P3 and P2-P4 macrocyclic structures, respectively. Quantitative Structure Activity Relationship (QSAR) characterization and docking simulations are performed in order to investigate the potential of these compounds as HCV NS3/4A protease inhibitors. Based on the QSAR properties, the three most stable compounds due to their lowest total energy are P1-P3 and P2-P4 macrocycles of azahexapeptide sequence (DDIVP vinyl amino cyclopropane) and P2-P4 macrocycle of azahexapeptide sequence (DDIVP norvaline). They also have high surface area, solvent accessible surface area, volume, molar refractivity and polarizabilty. They have moderately low dipole moment and good log P values, as well. The docking scores of the best two P2-P4 macrocycles are just acceptable. The two compounds 5A/5B hexapeptide sequence (DDIVP vinyl amino cyclopropane) and P2-P4 macrocycle of azapentapeptide sequence (DIVP vinyl amino cyclopropane) yielded the best docking scores.
Keywords: Docking, HCV, macrocyclic, NS3 protease, PM3, QSAR.
Current Computer-Aided Drug Design
Title:QSAR Analysis and Molecular Docking Simulation of Suggested Peptidomimetic NS3 Protease Inhibitors
Volume: 10 Issue: 1
Author(s): Hamdy I.A. Mostafa, Nihal. S. El-bialy, Ahmed A. Ezat, Noha. A. Saleh and Medhat A. Ibrahim
Affiliation:
Keywords: Docking, HCV, macrocyclic, NS3 protease, PM3, QSAR.
Abstract: Based on the N-terminal hexapeptide product of hydrolysis (EDVVCC) at HCV NS5A/5B junction, three modified groups of compounds are built. The first group contains linear peptides while the second and third groups contain P1-P3 and P2-P4 macrocyclic structures, respectively. Quantitative Structure Activity Relationship (QSAR) characterization and docking simulations are performed in order to investigate the potential of these compounds as HCV NS3/4A protease inhibitors. Based on the QSAR properties, the three most stable compounds due to their lowest total energy are P1-P3 and P2-P4 macrocycles of azahexapeptide sequence (DDIVP vinyl amino cyclopropane) and P2-P4 macrocycle of azahexapeptide sequence (DDIVP norvaline). They also have high surface area, solvent accessible surface area, volume, molar refractivity and polarizabilty. They have moderately low dipole moment and good log P values, as well. The docking scores of the best two P2-P4 macrocycles are just acceptable. The two compounds 5A/5B hexapeptide sequence (DDIVP vinyl amino cyclopropane) and P2-P4 macrocycle of azapentapeptide sequence (DIVP vinyl amino cyclopropane) yielded the best docking scores.
Export Options
About this article
Cite this article as:
Mostafa I.A. Hamdy, El-bialy S. Nihal., Ezat A. Ahmed, Saleh A. Noha. and Ibrahim A. Medhat, QSAR Analysis and Molecular Docking Simulation of Suggested Peptidomimetic NS3 Protease Inhibitors, Current Computer-Aided Drug Design 2014; 10 (1) . https://dx.doi.org/10.2174/15734099113096660048
DOI https://dx.doi.org/10.2174/15734099113096660048 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A New Bone Marrow Transplantation Method for the Prevention of Graft- Versus-Host Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Natural and Synthetic Furanocoumarins as Treatment for Vitiligo and Psoriasis
Current Drug Therapy Aggregation Suppression of Proteins by Arginine During Thermal Unfolding
Protein & Peptide Letters Effects of Follicular Helper T Cells and Inflammatory Cytokines on Myasthenia Gravis
Current Molecular Medicine Polycations Selectively Blocking Tissue Factor-Dependent FVII Activation: Collective In Vitro Anticoagulation Studies§
Inflammation & Allergy - Drug Targets (Discontinued) Interaction of Complement System Components with Bacterial Outer Membrane Proteins and Presentation of Techniques Useful in Studying these Interactions
Anti-Infective Agents ent-Abietane Lactones from Euphorbia
Mini-Reviews in Medicinal Chemistry Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design Mitochondrial Complex I Deficiency in Humans
Current Genomics Current Advances in Retroviral Gene Therapy
Current Gene Therapy Immune Therapy for Infectious Diseases at the Dawn of the 21st Century: the Past, Present and Future Role of Antibody Therapy, Therapeutic Vaccination and Biological Response Modifiers
Current Pharmaceutical Design Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis
Current Pharmaceutical Design Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Molecular Link between Intravascular Hemolysis and Vascular Occlusion in Sickle Cell Disease
Current Vascular Pharmacology Innovative Drug Delivery Systems for the Administration of Natural Compounds
Current Bioactive Compounds Structural and Molecular Tear Film Changes in Glaucoma
Current Medicinal Chemistry Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction?
Cardiovascular & Hematological Disorders-Drug Targets Flavonoids Health Benefits and Their Molecular Mechanism
Mini-Reviews in Medicinal Chemistry Use of Mouse Models to Evaluate Roles of Nuclear Receptors and their Ligands in the Pathogenesis and Treatment of Atherosclerosis
Current Drug Targets Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery